Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 27Neoplasm Metastasis 5Advanced Solid Tumors 5Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors (Excluding Breast Cancer) 2Urologic Diseases 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Renal Insufficiency 1Refractory Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Teclison Ltd.

Phase 2 Recruiting
110 enrolled
GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡